ESMO 2023 Insights: "The NICHE-3 Study on Neoadjuvant Nivo + Relatlimab (anti-LAG3) in Locally Advanced MMR-Deficient Colon Cancers"

0 views
October 31, 2023
Comments 0
Login to view comments. Click here to Login